Advertisement PolyRemedy raises $25 million in series B financing - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

PolyRemedy raises $25 million in series B financing

PolyRemedy has closed a $25 million investment from leading venture capital firms.

The series B financing was co-led by Advanced Technology Ventures and IDG Ventures Boston and included participation from series A investor, MedVenture Associates and new investor Harris & Harris Group, New York.

PolyRemedy also announced that Dan Eckert has joined the company as president and CEO and board member and Tom Rodgers from ATV and Michael Greeley from IDG Ventures will join the company’s board of directors, which includes Annette Campbell-White from MedVenture.